A Phase II Study to Evaluate the Efficacy and Safety of Selinexor in Patients With Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Selinexor (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Acronyms ESSENTIAL
Most Recent Events
- 08 Apr 2025 Planned End Date changed from 14 Mar 2025 to 1 May 2025.
- 18 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 08 Feb 2022 According to a Karyopharm Therapeutics media release, data presented at the upcoming American Society of Hematology (ASH) 2021 Annual Meeting and Exposition.